Harrow (HROW): Strong Product Momentum Meets A Steep H2 Revenue Target
Harrow Inc. (HROW) faces a significant challenge to meet its full-year revenue guidance of $350-$365 million after a first half that fell short. Despite strong product momentum with IHEEZO, VEVYE, and TRIESENCE, and the pending acquisition of TYRVAYA, the company needs to generate $235-$250 million in the second half compared to $115 million in the first half. Wall Street remains skeptical, with high short interest and a substantial forward P/E ratio.
Harrow, Inc.: Harrow Health, Inc. Announces IHEEZO Data in Patient-Reported Discomfort Following Intravitreal Injections
Harrow Health, Inc. announced positive results from a study evaluating IHEEZO (chloroprocaine hydrochloride ophthalmic gel) 3% for ocular surface anesthesia during intravitreal injections. The study showed statistically significant reductions in patient-reported discomfort with IHEEZO compared to proparacaine ophthalmic solution 0.5% at all measured time points. These findings suggest IHEEZO can improve patient comfort for the millions of intravitreal injections performed annually.
Harrow Announces IHEEZO® Data in Patient-Reported Discomfort Following Intravitreal Injections
Harrow announced positive results from a study showing that its IHEEZO® ophthalmic gel significantly reduced patient-reported discomfort following intravitreal injections. Patients experienced approximately 58% less discomfort with IHEEZO compared to proparacaine, especially immediately after injection. This finding is significant for retina specialists and patients undergoing frequent injections, as it highlights IHEEZO's potential to improve the patient experience.
In a 50-patient study, Harrow’s eye gel was linked to about 58% less injection discomfort
Harrow (Nasdaq: HROW) announced positive results from a study showing its IHEEZO (chloroprocaine hydrochloride ophthalmic gel) 3% significantly reduced patient-reported discomfort during intravitreal injections. In a 50-patient, contralateral-eye study, IHEEZO-treated eyes experienced approximately 58% less discomfort compared to eyes treated with proparacaine 0.5%, with statistically significant differences observed at all post-injection assessments over 24 hours. This data suggests IHEEZO offers a measurable improvement in patient comfort for a common ophthalmic procedure.
Harrow (HROW): Strong Product Momentum Meets A Steep H2 Revenue Target
Harrow Inc. (HROW) faces a significant challenge to meet its full-year revenue guidance of $350 million to $365 million after a softer first half. Despite strong product momentum in IHEEZO, VEVYE, and TRIESENCE, and an upcoming acquisition of TYRVAYA, the company needs to generate $235 million to $250 million in the second half, compared to $115 million in the first. Wall Street remains skeptical, with high short interest and a forward P/E ratio that already prices in substantial growth.
Harrow (HROW) Reaffirms 2026 Guidance, Is The Upside Already Priced In?
Harrow (HROW) reaffirmed its 2026 revenue guidance of US$350 million to US$365 million despite reporting higher sales but a wider net loss in Q2. The stock has seen a significant gain over the past three months but a recent pullback. A narrative suggests Harrow is 42.2% undervalued, with a fair value of $68.38, driven by growing demand for its ophthalmic drugs, though potential risks like reliance on key products and drug pricing pressure exist.
Harrow And 2 Other Growth Stocks Insiders Are Betting On
This article highlights three US growth companies with significant insider ownership: Harrow (HROW), Hennessy Capital Investment VII (HVII), and Alphatec Holdings (ATEC). Despite some current losses or early-stage operations, these companies are projected to have strong earnings and revenue growth, making them appealing to investors looking for potential long-term value. The report emphasizes that high insider ownership can signal confidence in future expansion and value creation.
Harrow CSO Amir Shojaei sells $450,000 in company stock
Amir Shojaei, Chief Scientific Officer at HARROW, INC., sold 11,250 shares of company stock worth $450,000 on August 14, 2026. This transaction involved the exercise of stock options to cover costs, with Shojaei acquiring and immediately selling shares, resulting in no retained shares from this specific option exercise. Despite this, Shojaei still holds 18,750 derivative securities, and InvestingPro analysis suggests HROW is undervalued with a Strong Buy consensus.
Harrow CSO Amir Shojaei sells $450,000 in company stock
Amir Shojaei, Chief Scientific Officer at HARROW, INC. (NASDAQ:HROW), sold 11,250 shares of company stock for $450,000 after exercising stock options. The sale was a broker-assisted transaction to cover the exercise price and associated costs, with Shojaei not retaining any of the acquired shares. This transaction follows recent news of Harrow Health reporting a wider-than-expected loss in Q2 2026, despite increased revenue.
Rice Hall James & Associates LLC Takes Position in Harrow, Inc. $HROW
Rice Hall James & Associates LLC has acquired a new position in Harrow, Inc. (NASDAQ:HROW), purchasing 387,545 shares valued at approximately $16.46 million, representing 1.04% of the company. Institutional investors now own 72.76% of Harrow, while insider Amir Shojaei recently sold 11,250 shares worth $450,000. Despite mixed analyst ratings, the consensus is a "Moderate Buy" with a target price of $69.43, even as the company reported a quarterly loss that missed expectations.
Will Harrow’s (HROW) TYRVAYA Deal and Reaffirmed 2026 Guidance Redefine Its Dry Eye Strategy?
Harrow, Inc. reported second-quarter revenue of US$70.66 million and a net loss of US$17.27 million, while reiterating its 2026 revenue guidance of US$350 million to US$365 million. The company recently agreed to acquire TYRVAYA nasal spray for up to US$100 million to expand its dry eye disease franchise, complementing its existing VEVYE offering. This acquisition, alongside the reaffirmed guidance, could redefine Harrow's investment narrative, although it also highlights the challenge of achieving sustained profitability while integrating new acquisitions.
Harrow (NASDAQ:HROW) Insider Amir Shojaei Sells 11,250 Shares
Harrow insider Amir Shojaei sold 11,250 shares of the company's stock for $450,000, reducing his ownership by 50%. This sale occurred on August 14th, with the stock trading down 1.4% to $39.47 on Monday. Despite missing earnings per share estimates, the company's revenue slightly exceeded expectations, and analysts maintain a "Moderate Buy" rating with an average price target of $69.43.
Royce Micro-Cap Fund's Harrow Inc(HROW) Holding History
This article provides the historical holding data of Harrow Inc (HROW) by Royce Micro-Cap Fund, showing no recent buys or sells. It also lists several related articles concerning Harrow Inc's financial performance, stock valuation, and earnings call highlights from Q2 2026. The content is hosted on GuruFocus.com, a financial data and analysis platform.
Wall Street Zen Upgrades Harrow (NASDAQ:HROW) to "Hold"
Wall Street Zen has upgraded Harrow (NASDAQ:HROW) from "sell" to "hold," though overall analyst sentiment remains a "Moderate Buy" with a target of $69.43. This comes as Harrow reported a quarterly loss that missed estimates despite slightly exceeding revenue expectations. Institutional investors hold a significant portion of the company's stock, and an insider recently purchased shares, while potential growth from new product commercialization is balanced against lowered earnings forecasts and ongoing profitability concerns.
Earnings Update: Harrow, Inc. (NASDAQ:HROW) Just Reported Its Second-Quarter Results And Analysts Are Updating Their Forecasts
Harrow, Inc. (NASDAQ:HROW) recently released its second-quarter results, showing revenues in line with expectations at US$71m, but statutory losses increased to US$0.46 per share. Following these results, analysts have updated their forecasts, predicting revenues of US$350.7m for 2026 but cutting EPS estimates significantly to US$0.14 per share, indicating a more bearish outlook. Despite the reduced earnings forecast, the consensus price target remains steady at US$67.50, suggesting analysts don't foresee a lower stock price due to the earnings revision.
Earnings Update: Harrow, Inc. (NASDAQ:HROW) Just Reported Its Second-Quarter Results And Analysts Are Updating Their Forecasts
Harrow, Inc. (NASDAQ:HROW) recently released its second-quarter results, showing revenues in line with expectations at US$71m but increased statutory losses of US$0.46 per share. Analysts have updated their forecasts, maintaining revenue predictions for 2026 at US$350.7m but significantly cutting EPS estimates from US$0.23 to US$0.14. Despite the lowered earnings outlook, the consensus price target remains steady at US$67.50, suggesting analysts believe the lower forecast earnings will not immediately impact the stock price.
Q2 2026 Harrow Inc Earnings Call Transcript
Harrow Inc. reported its Q2 2026 earnings, with revenues reaching $70.7 million, an 11% year-over-year increase, driven by strong performances in IHISO, Vevi, and Triessence products. Despite first-half revenues being lighter than expected due to Vevi's net revenue impact and IHISO inventory normalization, the company reiterated its full-year 2026 revenue guidance of $350-$365 million and adjusted EBITDA of $80-$100 million. The pending Tervaya acquisition is anticipated to be financially accretive, adding over $30 million in revenue by 2027, although it will also increase SG&A expenses.
HROW Reiterated by BTIG -- Price Target Maintained at $63
BTIG has reiterated its "Buy" rating for Harrow Inc (HROW), maintaining a price target of $63.00, which suggests the stock is currently undervalued by approximately 12.8% according to GuruFocus's GF Value™ of $44.53. Despite being unprofitable with a high forward P/E, the company shows positive insider buying activity and a moderate GF Score™ of 67/100, indicating strengths in valuation and profitability. Four gurus hold positions in HROW, with one increasing their stake.
Harrow, Inc. (NASDAQ:HROW) Receives Average Recommendation of "Moderate Buy" from Analysts
Harrow, Inc. (NASDAQ:HROW) has received an average rating of "Moderate Buy" from analysts, with eight out of eleven recommending a "buy" and an average 12-month price target of $69.43, significantly higher than its current price of $40.70. Despite falling short on profitability in recent earnings with a $0.34 loss per share against an expected $0.18 loss, the company reported revenues slightly above estimates. Insiders and institutional investors maintain substantial holdings, with recent share purchases by the CFO and a director indicating continued confidence.
Harrow Achieves Q2 Revenue Growth, Reiterates 2026 Full-Year Financial Guidance
Harrow announced its financial results for the second quarter ended June 30, 2026, reporting revenue of $70.7 million, a 60 percent sequential increase. The company reiterated its full-year 2026 financial guidance of $350 million to $365 million in revenue and $80 million to $100 million in adjusted EBITDA. Key developments include the commercial launch of Byooviz and the acquisition of Tyrvaya, positioning Harrow for accelerated growth.
How Profit-to-Loss Swing Despite Rising Sales At Harrow (HROW) Has Changed Its Investment Story
Harrow, Inc. (HROW) reported a swing from profit to a net loss in Q2 2026, despite rising sales, with net loss deepening to US$44.87 million over the first six months of 2026. This shift challenges the company's investment narrative, which relies on its expanding ophthalmic portfolio achieving sustainable profitability. The new partnership for the BYOOVIZ biosimilar is a key element that could help absorb elevated costs, though investors are cautioned about growing operating expenses.
Earnings Flash (HROW) Harrow, Inc. Reports Q2 Revenue $70.7M, Vs. FactSet Est of $70.4M
Harrow, Inc. (HROW) announced its Q2 financial results, reporting revenue of $70.7 million. This figure exceeded the FactSet estimate of $70.4 million. The flash earnings report highlights a positive performance for the company in the second quarter.
Harrow: Q2 Earnings Snapshot
This article provides a Q2 earnings snapshot for Harrow. As the provided content is minimal, no further details can be extracted regarding the financial performance or other specific results.
Harrow (NASDAQ:HROW) Posts Quarterly Earnings Results, Misses Expectations By $0.28 EPS
Harrow (NASDAQ:HROW) reported a quarterly EPS of ($0.46), missing analysts' consensus of ($0.18) by $0.28, despite revenue of $70.66 million slightly exceeding expectations. Shares of HROW traded up 0.6% following the announcement. The company has a "Moderate Buy" consensus rating from analysts, with insider buying activity also noted from the CFO and a director.
Harrow, Inc. (HROW) stock falls on Q2 2026 Earnings
Harrow, Inc. (HROW) reported its Q2 2026 earnings, with revenue increasing by 10.9% to $70.7 million, but the company faced pressure on profitability. The operating loss widened to $11.0 million, and the net loss attributable to common shareholders was $17.3 million, resulting in a diluted loss per share of $0.46 against an estimated $0.18. Following the earnings report, the stock declined by 1.75% after hours.
BRIEF-Harrow Inc Q2 Gross Margin 71%
Harrow Inc. reported a Q2 gross margin of 71%. The article is a brief financial update and directs readers to TradingView for full access to the Reuters article and other news sources.
Harrow Announces Second Quarter 2026 Financial Results
Harrow (Nasdaq: HROW) announced its second-quarter 2026 financial results, reporting a quarterly revenue of $70.7 million, a 60% sequential increase and 11% year-over-year increase. The company reiterated its full-year 2026 revenue guidance of $350 million to $365 million and Adjusted EBITDA of $80 million to $100 million. Key product VEVYE® saw significant growth, and the company completed the acquisition of TYRVAYA® and launched BYOOVIZ®, strengthening its ophthalmic disease management portfolio.
Harrow (HROW) Reports Q2 Loss, Misses Revenue Estimates
Harrow (HROW) reported a Q2 loss of $0.34 per share, missing the Zacks Consensus Estimate of a $0.23 loss, and revenues of $70.66 million, also below estimates. The company's shares have underperformed the S&P 500 this year, and its current Zacks Rank is #3 (Hold), indicating expected performance in line with the market. Investors will be looking to management's commentary and future estimate revisions for insights into the stock's direction.
Harrow earnings up next: Can ophthalmic firm stage Q2 comeback?
Harrow Health Inc. is set to report its second-quarter earnings, with analysts expecting a significant rebound in revenue and a narrowed loss after a disappointing first quarter. Despite unanimous "buy" ratings from analysts and a substantial implied upside, investors are keenly watching if the company can deliver on its 60% sequential revenue jump, improve its path to profitability, and demonstrate strong product portfolio momentum. The results will determine if Harrow can regain its footing in the competitive and growing ophthalmic drugs market.
HARROW HEALTH Q2 2026 Earnings Preview: Recent $HROW Insider Trading, Hedge Fund Activity, and More
This article previews HARROW HEALTH's (HROW) Q2 2026 earnings, expected on August 10th, with analysts forecasting $71.7 million in revenue and an EPS of -$0.18. It details recent insider trading activity, including both purchases and sales, and highlights significant hedge fund movements, with 83 institutional investors increasing and 110 decreasing their positions. The article also provides an overview of recent analyst ratings and price targets for HROW.
Dimensional Fund Advisors LP Grows Stock Holdings in Harrow, Inc. $HROW
Dimensional Fund Advisors LP significantly increased its stake in Harrow, Inc. (NASDAQ:HROW) by 56.4% in the first quarter, now holding 579,520 shares valued at approximately $20.4 million. This comes as Harrow reported weaker-than-expected quarterly results but maintains a "Moderate Buy" consensus rating from analysts with a target price of $69.43. Several other institutional investors also modified their holdings, and company insiders made recent stock acquisitions.
The only FDA-approved dry-eye nasal spray is set to join Harrow later in 2026
Harrow has entered an agreement to acquire global rights to TYRVAYA, the sole FDA-approved nasal spray for dry eye disease, from Viatris. The deal, valued at up to $100 million ($30 million upfront cash and up to $70 million in sales-tied milestones), is expected to close in the second half of 2026 and be financially accretive shortly thereafter. This acquisition expands Harrow's dry eye portfolio, complementing its VEVYE franchise with a differentiated, drop-free treatment option.
Form 8K Harrow Health Inc For: 6 August By Investing.com
Harrow Health Inc. (HROW) filed a Form 8K on August 6, 2026. This SEC filing typically indicates significant events that shareholders should know about. The article provides the title of the filing and its publication date, without detailing the specific content of the 8K.
Harrow Acquires Global Rights to TYRVAYA®, the First and Only FDA-Approved Nasal Spray for Dry Eye Disease
Harrow has acquired global rights to TYRVAYA® (varenicline solution) nasal spray from Viatris Inc. for up to $100 million. This acquisition significantly expands Harrow's dry eye portfolio, complementing its VEVYE franchise with a differentiated, drop-free treatment option for dry eye disease. The deal is expected to close in the second half of 2026 and aims to strengthen Harrow's market position by offering a broader range of therapeutic solutions for dry eye patients.
Harrow Acquires Global Rights to TYRVAYA®, the First and Only FDA-Approved Nasal Spray for Dry Eye Disease
Harrow has acquired global rights to TYRVAYA® (varenicline solution) nasal spray from Viatris Inc. for up to $100 million, including $30 million upfront. This acquisition expands Harrow's dry eye portfolio, complementing its VEVYE franchise by offering a differentiated, drop-free treatment option for dry eye disease. The company expects the transaction to strengthen its market position and be financially accretive shortly after closing, which is anticipated in the second half of 2026.
Opaleye Management (NASDAQ: HROW) discloses 6.44% Harrow ownership in latest filing
Opaleye Management Inc., along with Opaleye, L.P. and James Silverman, has reported a beneficial ownership of 6.44% in Harrow, Inc.'s Common Stock, totaling 2,400,000 shares. This disclosure was made in a SCHEDULE 13G/A filing and is based on 37,275,107 shares outstanding as of May 6, 2026. The reporting persons share both voting and dispositive power over these shares.
Harrow To Report Second Quarter 2026 Financial Results After Market Close on August 10, 2026
Harrow, Inc. (Nasdaq: HROW) announced it will report its financial results for the second quarter ended June 30, 2026, after market close on Monday, August 10, 2026. The company will also host a conference call and live webcast to discuss these results and provide a business update at 8:00 a.m. Eastern Time on Tuesday, August 11, 2026. Interested parties can access the call and webcast details via the company's website.
Harrow Inc (HROW) Valuation: PE, PB & Fair Value Analysis
This article provides a valuation analysis of Harrow Inc (HROW), noting its current valuation score of 9.51, which ranks 17th out of 155 companies in the Pharmaceuticals industry. It highlights the company's P/E ratio is -101.17, significantly below its recent high and above its recent low. The article also mentions that relevant data for P/B, P/S, and P/CF ratios have not yet been disclosed by the company.
Harrow To Report Second Quarter 2026 Financial Results After Market Close on August 10, 2026
Harrow, Inc. (Nasdaq: HROW), a leading provider of ophthalmic disease management solutions, announced it will report its Q2 2026 financial results after market close on Monday, August 10, 2026. The company will also host a conference call and live webcast on Tuesday, August 11, 2026, at 8:00 a.m. E.T. to discuss the results and provide a business update. A Letter to Stockholders will be posted on the "Investors" section of its website.
Harrow To Report Second Quarter 2026 Financial Results After Market Close on August 10, 2026
Harrow will report its second-quarter 2026 financial results after the market closes on Monday, August 10, 2026. The company will also host a conference call and live webcast on Tuesday, August 11, 2026, at 8:00 a.m. Eastern Time to discuss the results and provide a business update. Harrow is a leading provider of ophthalmic disease management solutions in North America.
Harrow Inc (HROW) Shareholder Structure: Major Shareholders & Institutional Holdings
This article details the shareholder structure of Harrow Inc (HROW), identifying its major shareholders and institutional holdings. It provides a breakdown of shareholder types, institutional shareholding trends over recent quarters, and recent shareholder activity with changes in holdings for key investors. The article also lists ETFs holding Harrow Inc shares.
Harrow Schedules Aug. 11 Call to Discuss Second-Quarter Results
Harrow (Nasdaq: HROW) will report its second-quarter 2026 financial results after the market close on Monday, August 10, 2026. The company will also host a conference call and live webcast to discuss the results and provide a business update at 8:00 a.m. Eastern Time on Tuesday, August 11, 2026. A replay of the webcast will be available on Harrow's investor website for one year.
Harrow To Report Second Quarter 2026 Financial Results After Market Close on August 10, 2026
Harrow, Inc. (Nasdaq: HROW) announced it will report its financial results for the second quarter ended June 30, 2026, after market close on Monday, August 10, 2026. The company will also host a conference call and live webcast on Tuesday, August 11, 2026, at 8:00 a.m. Eastern Time to discuss the results and provide a business update. A Letter to Stockholders will be posted on the company's website in the "Investors" section.
Harrow Inc (HROW) Dividends & Stock Splits: Historical Payouts and Event Timeline
The article provides a dividend and stock split history for Harrow Inc (HROW), indicating that the company has not distributed any dividends over the past five years. It also presents current stock performance data, including a market capitalization of $1.43 billion.
Harrow, Inc. Revenue Breakdown – NASDAQ:HROW
Harrow, Inc. (NASDAQ: HROW) generated $272.30 million in revenue last year. Its top-performing segment, Branded, contributed $195.76 million, an increase from $116.11 million the previous year. All of the company's revenue came from the United States market.
Harrow Inc (HROW) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution
This article provides a revenue breakdown for Harrow Inc (HROW), detailing its business segments. It lists Product Sales Net at $271.91 million and Transfer of acquired product sales/profit at $394.00 thousand, noting that relevant data has not yet been disclosed by the company for these segments. The article also provides the basic financial overview of the company including its market cap.
HROW|Harrow Inc|Price:39.409|Chg%:+0.959
This article provides a comprehensive stock analysis of Harrow Inc (HROW), highlighting its strong fundamentals, high growth potential, and "Buy" rating from multiple analysts with a target price of $65.57. Despite recent weak market performance, the company's stock is considered fairly valued and is trading sideways, making it suitable for range-bound swing trading. The analysis also details Harrow Inc's eyecare pharmaceutical business, including its product portfolio and institutional ownership.
Harrow Inc HROW Income Statement
This article provides a detailed quarterly and annual income statement for Harrow Inc (HROW), offering insights into its financial performance and operational efficiency. It presents data spanning several fiscal years for key metrics such as total revenue, cost of revenue, operating expenses, and net income. The article also includes FAQs to help users interpret the financial data presented on TradingKey.
Harrow Inc (HROW) Institutional Confidence
Harrow Inc (HROW) has an institutional shareholding score of 5.00, placing it 72nd out of 155 in the Pharmaceuticals industry. The institutional shareholding proportion increased by 12.15% quarter-over-quarter to 66.17%. Private Capital is the largest institutional shareholder, holding 4.19% of outstanding shares.
BTIG Maintains Harrow(HROW.US) With Buy Rating, Maintains Target Price $63
BTIG has reiterated its Buy rating for Harrow (HROW.US) and maintained its target price at $63.00. This suggests a continued positive outlook from the firm regarding the company's stock performance.
